Advertisement
UK markets close in 1 hour 4 minutes

  • FTSE 100

    7,869.22
    +21.23 (+0.27%)
     

  • FTSE 250

    19,372.54
    +32.40 (+0.17%)
     

  • AIM

    743.69
    +0.57 (+0.08%)
     

  • GBP/EUR

    1.1682
    +0.0015 (+0.13%)
     

  • GBP/USD

    1.2446
    -0.0010 (-0.08%)
     

  • Bitcoin GBP

    51,125.61
    +1,835.52 (+3.72%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,034.49
    +12.28 (+0.24%)
     

  • DOW

    37,971.90
    +218.59 (+0.58%)
     

  • CRUDE OIL

    82.84
    +0.15 (+0.18%)
     

  • GOLD FUTURES

    2,398.20
    +9.80 (+0.41%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     

  • DAX

    17,796.98
    +26.96 (+0.15%)
     

  • CAC 40

    8,015.16
    +33.65 (+0.42%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020

ObsEva SA
·1-min read

Geneva, Switzerland and Boston, MA – September 8, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the H.C Wainwright 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020.

Mr. Loumaye’s presentation will take place on Wednesday September 16 at 12:00 p.m. Eastern Time (ET). A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

ADVERTISEMENT

For further information, please contact:

CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Mario Corso
Vice President, Investor Relations
mario.corso@obseva.com

+1 857 972 9347 Office
+1 781 366 5726 Mobile

Attachment